ArticleBMC musculoskeletal disorders2026
3D printed microporous titanium prosthesis for single implantation or combined with free flap for infected bone defects in the limbs: a single-center retrospective cohort study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study represents the largest single-center cohort to date evaluating the early- and mid-term safety and effectiveness of a staged reconstructive strategy using 3D-printed microporous titanium prostheses, applied either alone or in combination with free flap reconstruction, for the management of infected bone defects.
methodsPatients treated between January 2019 and January 2025 were retrospectively identified from electronic medical records. Primary outcomes included changes in Visual Analogue Scale (VAS) scores and Lower Extremity Functional Scale (LEFS) scores at 3, 6, and 12 months, as well as at the last follow-up. Secondary outcomes included implant integration, postoperative functional recovery milestones for lower-extremity cases, and complication profiles.
resultsThis study included 80 consecutive patients (54 males, 26 females) with an average age of 47.5 ± 9.3 years and an average follow-up time of 40.8 ± 14.8 months. At follow-up time points of 3 months and beyond, VAS scores significantly decreased compared to preoperative levels (p < 0.0001), and lower extremity LEFS scores significantly improved (p < 0.0001). At 12 months postoperatively, 69 cases (86.3%) were rated as “Excellent” in terms of implant integration. Subgroup analyses demonstrated that both the single microporous titanium group and the combined free flap group experienced significant improvements in pain relief, functional scores, and postoperative lower-extremity functional recovery over time. Eight patients reported complications, including 6 cases of recurrent infection and 2 cases of prosthesis or screw fractures. A history of diabetes and mixed bacterial infections were significantly associated with a higher risk of recurrent infection (p < 0.05).
conclusionsPreliminary evidence suggests that both the single porous titanium group and the combined free flap group exhibited sustained pain relief and continuous improvement in lower-limb function, with relatively low complication rates. Relying on advanced microsurgical techniques to obtain free flaps and implementing stratified treatment for diabetic patients are crucial for orthopedic surgeons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.